Stock Price & Volume | Full Chart
30-Day Implied Volatility | IV30 Full Chart
Why did Tandem Diabetes Care stock go down today?
Seeking Alpha News (Wed, 29-Mar 4:31 PM ET)
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII
Business Wire (Wed, 29-Mar 3:14 PM ET)
Abbott Hosts Conference Call for First-Quarter Earnings
PRNewswire (Wed, 29-Mar 9:00 AM ET)
FDA strategy aims to avoid another baby formula shortage
Seeking Alpha News (Tue, 28-Mar 2:35 PM ET)
Global continuous glucose monitoring market to hit $32B by 2031 – report
Seeking Alpha News (Sun, 26-Mar 12:00 PM ET)
Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement
PRNewswire (Thu, 23-Mar 9:00 AM ET)
Continuous Glucose Monitoring Systems Market Size is Likely to Grow US$ 9.56 Billion by 2027 At a CAGR 9.50%
AB Digital, Inc. (Tue, 21-Mar 6:05 PM ET)
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
Globe Newswire (Mon, 20-Mar 8:00 AM ET)
Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion
PRNewswire (Tue, 7-Mar 9:00 AM ET)
U.S. FDA Clears Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 Sensors for Integration with Automated Insulin Delivery Systems
PRNewswire (Mon, 6-Mar 7:00 AM ET)
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of March 31, 2023, ABT stock price climbed to $101.37 with 2,709,226 million shares trading.
ABT has a beta of 0.72, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.41 to the broad based SPY ETF.
ABT has a market cap of $176.18 billion. This is considered a Large Cap stock.
Last quarter Abbott Laboratories reported $10 billion in Revenue and $1.03 earnings per share. This beat revenue expectation by $451 million and exceeded earnings estimates by $.11.
In the last 3 years, ABT stock traded as high as $142.60 and as low as $75.35.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, VOO, SPY, VTV, IVV.
ABT has underperformed the market in the last year with a price return of -14.2% while the SPY ETF lost -9.4%. ABT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.2% and +2.4%, respectively, while the SPY returned +7.3% and +4.0%, respectively.
ABT support price is $97.65 and resistance is $100.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT stock will trade within this expected range on the day.